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Based on preliminary evidence that highlights microRNA-122 as a contributing factor to stroke pathogenesis, we aimed at assessing
its expression level, along with the presence of early signs of cerebrovascular disease, in the brain of stroke-prone spontaneously
hypertensive rat (SHRSP), a suitable model of human disease that accelerates stroke occurrence under a high sodium/low
potassium (Japanese-style) diet (JD). After one month of JD, before stroke occurrence, brain microRNA-122 level was
significantly decreased in SHRSP as compared to the stroke-resistant SHR (SHRSR). At this time, levels of markers of oxidative
stress and inflammation, as well as of endothelial integrity and function, apoptosis and necrosis were differently modulated in
the brains of JD-fed SHRSP as compared to SHRSR, pointing to a significant activation of all deleterious mechanisms
underlying subsequent stroke development in SHRSP. We also showed that miR-122 improved survival of rat endothelial
cerebral cells upon stress stimuli (excess NaCl, hydrogen peroxide). Our data suggest that a decrease of brain microRNA-122
level is deleterious and can be considered as an early marker of stroke in the SHRSP. Understanding the mechanisms by which
microRNA-122 protects vascular cells from stress stimuli may provide a useful approach to improve preventive and treatment
strategies against stroke.
1. Introduction
Stroke, a leading cause of death and disability worldwide,
represents a multifactorial disease resulting from the com-
plex interaction of multiple genetic and environmental
factors [1, 2]. Hypertension is a major risk factor for stroke
[3]. Interestingly, the contributory role of an epigenetic
modulation into stroke predisposition has been recently
underscored [4]. In particular, microRNAs, a family of
important posttranscriptional regulators of gene expression
acting on multiple epigenetic levels [5], are expressed in acute
ischemic stroke where they appear to play a key contributory
role as a main consequence of their vascular effects [6]. Thus,
the expression level of few microRNAs can be differently
modulated in both experimental models and ischemic stroke
patients [6–11]. As a consequence, the potential role of
microRNAs as circulating biomarkers for the detection
of stroke has been implied [12]. Among others, the
microRNA-122 (miR-122) level was significantly reduced in
the blood of ischemic rats [8] and in both blood and brain
tissues of the middle cerebral artery occlusion (MCAO) rat
model [9]. In the latter model, intravenous administration
of exogenous miR-122 led to inhibition of proteins involved
in inflammation such as intercellular adhesion molecule 1
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(ICAM-1) and, most importantly, to reduced brain injury
and neurological deficits [9]. Notably, a decrease of miR-
122 level was also detected in blood cells of acute ischemic
stroke patients [7, 10, 11]. Herein, the involvement of
miR-122 on the regulation of several genes and pathways
associated with ischemic stroke, including leukocytes acti-
vation and thrombus formation, was demonstrated [10].
The stroke-prone spontaneously hypertensive rat
(SHRSP) is a suitable model for studies of human disease.
The exposure to a high sodium/low potassium Japanese-
style diet (JD) accelerates the predisposition to spontaneous
stroke leading to 100% phenotype occurrence by the 7th
week of treatment [13, 14]. At the end of one month of
JD feeding, the molecular mechanisms predisposing to
cerebrovascular disease, such as mitochondrial dysfunction,
increased oxidative stress and inflammation, and endothelial
dysfunction, are already activated [15–17].
Based on the previous evidence linking epigenetics with
stroke occurrence, and in order to reinforce the involvement
of miR-122 in this pathological condition, we presently tested
the hypothesis that a derangement of brain miR-122 expres-
sion level could be an early marker of cerebrovascular disease
in our animal model. For this purpose, the brain miR-122
level was assessed at the end of one month of JD feeding in
SHRSP, before the stroke phenotype occurrence.
2. Materials and Methods
2.1. Animal Study Design. Male inbred SHRSP and stroke-
resistant spontaneously hypertensive rats (SHRSR) were used
for these studies. Animals were kept at a constant tempera-
ture with a 12hrs day–night cycle, with free access to regular
rat chow and water. According to our standardized experi-
mental protocol [13–17], 8 SHRSP and 8 SHRSR were shifted
at 6 weeks of age to a stroke permissive diet (JD, Laboratory
Dottori Piccioni, Milan, Italy) and 1% NaCl supplemented in
the drinking water for 4 weeks. A second group of 8 SHRSP
and 8 SHRSR was fed with regular diet (RD) and used
as control. At the end of 4 weeks of either treatment, rats
were sacrificed by cervical dislocation and the brains were
removed for total RNA and protein extraction, as well as
for histological analysis. The personnel who performed the
laboratory analyses was unaware of the experimental group
allocation. All experimental procedures were performed
in accordance with our institutional guidelines (DLGS 26/
2014), and they were approved by the Neuromed institutional
committee for experimental work (OPBA=organization for
the animal welfare).
2.2. Brain Molecular Studies
2.2.1. Quantitative RT-PCR of MicroRNA-122 (TaqMan
Methodology). In order to assess the brain miR-122 expres-
sion level in SHRSP and SHRSR under both JD and RD,
tissue total RNA was obtained using TRIzol reagent (Life
Technologies, Carlsbad, CA, USA), subjected to DNAse I
treatment (Qiagen, Venlo, Netherlands) and subsequently
purified using miRNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. RNA integrity was assessed
by denaturing agarose gel electrophoresis and its concentra-
tion was verified by using NanoDrop2000c UV-Vis spec-
trophotometer (Thermo Scientific, Waltham, MA). Then,
RT-PCR of miR-122 was performed through the use of a
specific TaqMan microRNA assay (Applied Biosystems,
Foster City, USA) using miRU87 as control. For this pur-
pose, 1μg of purified RNA was mixed with 3μl of NCode
VILO miRNA cDNA Synthesis Kit (Life Technologies)
and 1x RT-primer (Life Technologies) in a total reaction
volume of 20μl. Reaction was incubated at 16°C for
30min., 42°C for 30min, and 85°C for 5min in a T-100
Thermal Cycler (Bio-Rad, Hercules, CA, USA). Then, 2μl
of the RT reaction was added to 1μl of a specific TaqMan
microRNA assay 20x and 10μl of TaqMan Universal PCR
Master Mix II with UNG (Life Technologies) in a 20μl
final volume. RT-PCR was performed using the ViiA 7
Real-Time PCR System with cycling conditions of 95°C
for 10min and followed by 95°C for 15 s and 60°C for
60 s for a total of 40 cycles. Measurements were performed
in triplicate. Results were expressed as relative levels of
miR-122 under the different experimental conditions.
2.3. Protein Expression Analysis byWestern Blot of gp91-phox,
NF-kB, ICAM-1, vWF, CD31, eNOS, Caspase-3 (Cleaved
Caspase-3), and c-Jun. For this purpose, total proteins were
extracted from the brains of SHRSP and SHRSR at the end
of either RD or JD treatment. Tissues were weighted and
homogenized at 4°C in Triton-X lysis buffer 3 (10mM
Tris-HCl, pH7.4, 150mM NaCl, 1% Triton X-100, 1mM
EDTA, 10% glycerol, 1mM phenylmethylsulfonyl fluo-
ride, 10μg/ml leupeptin, 10μg/ml aprotinin, 1mM sodium
orthovanadate, 50mM sodium fluoride, and 10mM ß-glyc-
erophosphate, all reagents purchased from Sigma-Aldrich,
Milan, Italy). After 20min of incubation on ice, samples were
centrifuged at 12,000 rpm for 20min at 4°C. The superna-
tants containing soluble proteins were collected. Protein
concentrations were determined by the Bradford method
[18]. 60μg of total proteins were separated on 12%
SDS-PAGE and transferred to polyvinylidene difluoride
membranes (Amersham, Piscataway, New Jersey, USA).
Nonspecific binding sites were blocked with 5% nonfat
dried milk for 2 hrs at room temperature. Membranes
were then incubated overnight with the following primary
antibodies: anti-gp91-phox (1 : 200 goat polyclonal anti-
body; Santa Cruz Biotechnology, Santa Cruz, CA, USA);
anti-NF-κB p65 (nuclear factor kappa B; 1 : 200 mouse
monoclonal antibody; Santa Cruz Biotechnology); anti-
eNOS (endothelial nitric oxide synthase; 1 : 200 mouse
monoclonal antibody; Cell Signaling Technology, MA,
USA); anti-phospho-eNOS (Ser1177) (1 : 200 rabbit poly-
clonal antibody; Cell Signaling Technology); anti-vWF (von
Willebrand Factor); (1 : 200 goat polyclonal antibody; Santa
Cruz Biotechnology); anti-ICAM-1 (1 : 200 mouse monoclo-
nal antibody; Santa Cruz Biotechnology); anti CD31 (1 : 200
mouse monoclonal antibody; BD Pharmigen, 2350 CA,
USA); anti-c-Jun (1 : 200 mouse monoclonal antibody;
Cell Signaling Technology); anti-Caspase-3 (1 : 200 rabbit
monoclonal antibody; Cell Signaling Technology); anti-β-
actin (1 : 5000 mouse monoclonal antibody; Sigma Aldrich).
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Secondary antibodies were goat anti-rabbit IgG-HRP
(1 : 5000; Santa Cruz Biotechnology) and goat anti-mouse
IgG-HRP (1 : 5000; Santa Cruz Biotechnology). After three
washes of 10min in Tween TBS, signals were revealed
with an enhanced chemiluminescence detection system
(Luminata Crescendo, Millipore, Darmstadt, Germany) and
the immunoreactivity of bands was visualized on a high-
performance chemiluminescence apparatus (ChemiDoc MP
System, Bio-Rad). Protein bands were scanned and quanti-
fied densitometrically. They were finally normalized using
β-actin levels.
2.4. Brain Histology. The brains of SHRSP and SHRSR,
obtained at the end of either RD or JD treatment, were
dissected out and fixed in a solution composed of ethanol
(60%), acetic acid (10%), and chloroform (30%) (Carnoy
fixative) and embedded in paraffin. For histological analysis,
coronal sections (10μm) were used for staining with hema-
toxylin/eosin (H/E). Deparaffinized sections were stained
with hemotoxylin (Diapath, BG, Italy) for 4min and then
with eosin (Diapath) for 2.5min. Cerebral blood vessel
integrity was assessed under light microscopy using six cor-
onal sections from each brain. H/E stained sections were
photographed with a microscope (Zeiss, Jena, Germany)
fitted with a digital camera. Analysis of cortical and striatal
blood vessels was performed in randomly chosen 63x
microscopic fields.
2.5. In Vitro Effects of Mimic miRNA-122 on Rat Brain
Microvascular Endothelial Cells Viability. In order to support
the in vivo findings and the hypothesis that miR-122 may
be involved in cerebrovascular disease pathogenesis, we
tested in vitro the ability of miR-122 to maintain cell sur-
vival upon two different stress stimuli. For this purpose,
2× 105 cells/well rat brain microvascular endothelial cells
(MEC, Innoprot Bizkaia, Spain) were seeded in precoated
fibronectin 6 multiwell plates and cultured in endothelial
cell medium (ECM) supplemented with 10% fetal bovine
serum, endothelial cell growth supplements, and antibiotics,
to reach a 70–80% confluence. Then, different sets of dishes
received either medium supplemented with 20mM NaCl
(high-NaCl medium) for 72 hrs or with 200μM H2O2 for
24 hrs. The same stimuli were applied to cell dishes in the
presence of exogenous mimic miR-122 overexpression. For
the latter purpose, a specific miR-122 mimic (miRvana
miRNA mimic, Thermo Fisher, Waltham, USA) was
incubated in OPTIMEM (Thermo Fisher) reduced serum
medium with a nucleic acid transferring agent (lipofectamine
RNAiMAX reagent, Invitrogen, Carlsbad USA) in a final
volume of 2ml/well each for 20min, following the manu-
facturer’s instructions. Five hours later, the complex was
replaced with complete ECM, containing the specific treat-
ment (either 20mM NaCl or 200μM H2O2). Cells trans-
fected with RNAiMax lipofectamine complex were used as
negative control. At the end of each stress exposure, per-
formed both in the absence or in the presence of exogenous
mimic miR-122, we assessed the effect of miR-122 on cell
viability, apoptosis, and necrosis by fluorescent-activated
cell sorting (FACS) (Accuri C6 flow cytometer, BD
Biosciences, San Jose, CA, USA), following previously
reported procedures (16).
In order to assess the efficiency of mimic miR-122
transfection, levels of miR-122 were measured through
RT-PCR, as reported above.
2.6. Statistical Analysis. All values are shown as means±
S.E.M. Statistical analysis of RT-PCR results was performed
by one-way ANOVA followed by Bonferroni post hoc test.
In the Western blot analyses, the densitometric data compar-
isons between 2 groups were performed using Student t-test
followed by post hocMann–Whitney test. For FACS analysis,
two-way ANOVA followed by Bonferroni post hoc test was
performed. The correlation between miR-122 levels and
protein expression levels was conducted by using the Pearson
correlation test. Statistical significance was stated at the
P < 0 05 level. GraphPad Prism (Ver 5.01 GraphPad Soft-
ware, Inc. La Jolla, CA, USA) statistical software was used
for the statistical analysis.
3. Results
3.1. Brain Expression of MicroRNA-122 in SHRSP and
SHRSR. At the end of 4 weeks of dietary treatment, miR-
122 expression level was significantly increased in the brains
of JD- versus RD-fed SHRSR, whereas it was significantly
decreased in the brains of JD- versus RD-fed SHRSP
(Figure 1(a)), thus reproducing previous findings in other
animal models and in humans [7–11].
3.2. Protein Expression of gp91-phox and NF-kB. Next, to
verify and confirm that mechanisms of cerebrovascular
damage have been already activated at the end of 4 weeks
of JD treatment in SHRSP, before stroke occurrence, we
evaluated the brain expression level of proteins involved in
the oxidative stress and inflammatory processes. In fact,
whereas level of gp91-phox was unchanged and that of NF-
kB was significantly decreased in the brains of JD- versus
RD-fed SHRSR (Figure 1(b)), a significant increase of both
gp91-phox and NF-kB was detected in the brains of JD-
versus RD-fed SHRSP (Figure 1(c)), confirming previous
evidence [16].
3.3. Protein Expression of vWF, ICAM-1, CD31, and eNOS.
In parallel, the protein expression level of all markers of
endothelial integrity and function was differentially regulated
in the brain of the two strains. Notably, vWF and ICAM-1
were previously reported to be modulated in association with
miR-122 changes in animal models of ischemic stroke [9].
Our results highlighted a significant increase of both vWF
and ICAM-1 in the brains of JD- versus RD-fed SHRSP,
whereas levels of vWF were significantly decreased and those
of ICAM-1 were unchanged in JD- versus RD-fed SHRSR
(Figures 2(a) and 2(b)). Levels of CD31 were also signifi-
cantly upregulated only in the brain of JD-fed SHRSP
(Figure 2(c)). A significant increase of brain expression level
of eNOS was observed in JD-fed as compared to RD-fed
SHRSR, whereas eNOS failed to increase in JD- versus
RD-fed SHRSP, as a hallmark of endothelial dysfunction
[19] (Figure 2(d)).
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Figure 1: Characterization of brain expression level of microRNA-122, gp 91-phox, and NF-kB protein expression levels in JD-fed versus
RD-fed SHRSR and SHRSP strains. (a) miR-122 expression level, as detected by RT-PCR, in the brains of RD- and JD-fed SHRSR and
SHRSP; ∗p < 0 05 JD- versus RD-fed SHRSP; ∗∗p < 0 001 JD- versus RD-fed SHRSR; ∗∗∗p < 0 0001 JD-fed SHRSR versus JD-fed SHRSP.
(b) Protein expression level of gp91-phox and of NF-kB in SHRSR upon the two diets; ∗p < 0 05 JD- versus RD-fed SHRSR; (c) protein
expression level of gp91-phox and of NF-kB in SHRSP upon the two diets. ∗∗∗p < 0 0001 JD- versus RD-fed SHRSP. Representative
Western blots and corresponding densitometric analysis are shown in panels (a) and (b). JD= high-salt Japanese style diet; RD= regular
diet. N = 8 for each experimental group.
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Figure 2: Continued.
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3.4. Protein Expression of Cleaved Caspase-3 and c-Jun. A
significant increase of both cleaved caspase-3 and c-Jun
proteins expressions was observed in the brain of JD-fed
SHRSP but not in JD-fed SHRSR (Figures 3(a) and 3(b)),
pointing to a clear evidence that apoptosis and necrosis
were already detectable at this early stage of cerebrovascular
disease [13, 14].
3.5. Correlation Analysis between miR-122 and Protein
Expression Levels in the Two Strains. The results of the
correlation analysis between miR-122 and protein expression
levels are shown in Figure 4 (SHRSP strain) and in Figure 5
(SHRSR strain). By performing this statistical test, we
were able to obtain a significant linear inverse relationship
between miR-122 level and levels of Gp91phox, Nf-kB,
vWF, ICAM1, CD31, c-Jun, and caspase 3 in the SHRSP
(Figure 4). A significant direct relationship was detected only
with levels of p-eNOS in this strain (Figure 4).
On the other hand, levels of miR-122 in the SHRSR
positively correlated with CD31 and p-eNOS levels, whereas
they negatively correlated with the levels of NF-kB, caspase 3,
and vWF (Figure 5).
3.6. Brain Histology. Histological analysis of cortical and
striatal blood vessels of either strain at the end of 4 weeks
of high-salt dietary treatment did not provide evidence of
vascular damage. In fact, we detected the presence of intact
cerebral blood vessels, without signs of vascular alterations,
in all examined experimental groups (Figure 6). These data
demonstrate that the considered temporal window (4 weeks
of high-sodium/low-potassium Japanese-style dietary treat-
ment) is not characterized by the presence of vascular
damage in either strain, confirming previous evidence [13].
3.7. Impact of miRNA122 on Cell Viability, Apoptosis, and
Necrosis in MECs. The efficiency of miR-122 mimic transfec-
tion was validated by RT-PCR. Levels of miR-122 increased
in cells transfected with mimic miR-122 (5.32± 0.05 fold
changes versus nontransfected cells at 24 hrs; 5.84± 0.032
fold changes versus nontransfected cells at 72 hrs).
Treatment with either high-NaCl medium (Figures 7(a)
and 7(b)) or medium supplemented with 200μM H2O2
(Figures 7(c) and 7(d)) significantly reduced the viability of
MECs, with a concomitant increase of cell apoptosis and
necrosis. The transfection with mimic miR-122 of MECs
exposed to either NaCl or H2O2 rescued the cell viability
and reduced apoptosis and necrosis in a significant manner.
4. Discussion
In the current study, we pursued the hypothesis that an
epigenetic modulation that appears to play a relevant con-
tributory role in other experimental contexts [4] may be
involved in the increased stroke susceptibility of the SHRSP
animal model and may provide an early marker of disease.
Interestingly, we detected a differential modulation of brain
miR-122 expression level after 4 weeks of high-salt dietary
regimen, before stroke occurrence, in the SHRSP as com-
pared to the SHRSR strain. In particular, the brain miR-122
expression level was significantly increased in the SHRSR,
whereas it was significantly decreased in the SHRSP. In the
latter strain, the miR-122 decrease was associated with the
early signs of cerebrovascular damage. In fact, substantial
changes in markers of oxidative stress, inflammation, endo-
thelial dysfunction, apoptosis, and necrosis could be detected
along with the miR-122 decrease in the brains of SHRSP. In
vitro, the overexpression of miR-122 revealed a significant
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Figure 2: Characterization of protein expression level of vWF, ICAM-1, CD31, and eNOS in the brains of JD- versus RD-fed SHRSR and
SHRSP strains. Representative Western blots with corresponding densitometric analysis are shown for the four indicated proteins in the
two strains (SHRSR, left side; SHRSP, right side). (a) vWF expression level; ∗p < 0 05 JD- versus RD-fed SHRSR; ∗∗p < 0 001 JD- versus
RD-fed SHRSP. (b) ICAM-1 expression level; ∗∗∗p < 0 0001 JD- versus RD-fed SHRSP. (c) CD31 expression level; ∗∗p < 0 001 JD- versus
RD-fed SHRSP. (d) eNOS and phospho-eNOS expression level; ∗p < 0 05 JD- versus RD-fed SHRSR. JD= high-salt Japanese style diet;
RD= regular diet. N = 8 for each experimental group.
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protective effect on survival in cerebral endothelial cells
exposed either to excess NaCl or to hydrogen peroxide.
The SHRSP represents a suitable animal model to inves-
tigate the mechanisms involved in the increased stroke
susceptibility associated with hypertension. Previous findings
obtained in this model have been successfully translated
to the human disease [20]. We have shown that SHRSP
develops 100% stroke occurrence by the 7th week of a
high-salt dietary regimen [12, 13] and that, by the end
of 4 weeks of this dietary treatment, mechanisms of cellular
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Figure 3: Characterization of brain expression level of cleaved caspase-3 and c-Jun in JD- versus RD-fed SHRSR and SHRSP strains.
(a) Representative Western blots with corresponding densitometric analysis are shown for c-Jun and cleaved caspase-3 in the brains
of RD- and JD-fed SHRSR. (b) Representative Western blots with corresponding densitometric analysis are shown for c-Jun and
cleaved caspase-3 in the brains of RD- and JD-fed SHRSP. ∗∗∗p < 0 0001 JD- versus RD-fed SHRSP. JD= high-salt Japanese style
diet; RD= regular diet. N = 8 for each experimental group.
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and vascular damage have been already activated with
evidence of increased inflammation, increased oxidative
stress, and endothelial dysfunction [14–16].
We had already reported an increase of NF-kB, a marker
of inflammation, and of oxidized total proteins at the end
of 4 weeks of JD in SHRSP [16]. In the current study, the
expression level of gp91-phox confirmed the previous evi-
dence of a substantial increase of oxidative stress at this
experimental stage [16]. The parallel rise of ICAM-1,
observed in the present study, goes along with previous
findings obtained in the SHRSP, where a decrease of this
inflammatory and endothelial integrity marker represented
a substantial achievement of strategies aimed to combat
stroke [21–23]. ICAM-1 is a cell surface glycoprotein that
is typically expressed in injured endothelial cells, and it plays
a well-known effect in facilitating endothelial leukocyte
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Figure 4: Correlation analysis between miR-122 and protein expression levels in the SHRSP strain. Scatter plots showing the results of the
correlation analysis performed between miR-122 expression level and each examined protein level in the brain of SHRSP.
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Figure 5: Correlation analysis between miR-122 and protein expression levels in the SHRSR strain. Scatter plots showing the results of the
correlation analysis between miR-122 expression level and each examined protein level in the brain of SHRSR.
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transmigration [24]. It has been previously associated with
miR-122 levels in other experimental models of stroke [9].
In addition, herein, we report the first evidence that an
increase of vWF and of CD31 expression is a distinct trait
of the early phase of disease in SHRSP. The vWF is a blood
glycoprotein, expressed also in endothelial cells, involved in
hemostasis. Its increase has been associated with endothelial
dysfunction and inflammation [25], and with increased
risk of stroke [26]. CD31 is a cell adhesion molecule
involved in inflammation and vascular biology including
angiogenesis, leukocyte transmigration, leukocyte motility,
thrombosis, vascular permeability, and numerous immune
functions [27]. Its increased expression has been related, as
a marker of angiogenesis, to the improvement of neurological
outcomes in ischemic stroke rats treated with autologous
peripheral blood-derived endothelial progenitor cells [28].
eNOS is the well-known nitric oxide producing enzyme
in the endothelium [29] with potential therapeutic implica-
tions in stroke [30]. Its brain expression has been previously
compared between SHRSP and Wistar Kyoto (WKY) rat
strains with evidence of a significant downregulation in the
stroke-prone rat [31]. Moreover, we reported a trend of
eNOS to decrease with aging in the brains of SHRSP but
not of SHRSR [32]. In the current study, we obtained
the first demonstration that phospho-eNOS, as a hallmark
of endothelial dysfunction, was significantly upregulated in
the brains of SHRSR whereas it tended to decrease in the
brains of SHRSP at the end of 4 weeks of JD feeding.
Finally, the significant observed increase of markers of
apoptosis and necrosis in the brains of SHRSP may repre-
sent the expected result of all above identified mechanisms
and the most suitable pathological background for the
subsequent cerebrovascular event. In fact, at this experi-
mental stage, it is hard to observe evidence of histological
brain damage [13].
The SHRSR strain is known for its stroke resistance,
even when fed with a high-salt Japanese-style diet, along
with the lack of brain inflammation and of oxidative stress
after 4 weeks of JD feeding [13–16], as well as with the
aging process [33]. The current data, showing a different
expression of genes involved in inflammation, oxidative
stress, endothelial integrity, apoptosis, and necrosis, as com-
pared to SHRSP, are consistent with the previous findings,
and they are certainly the consequence of a specific genetic
background causing stroke resistance as opposed to stroke
proneness [13]. Interestingly, based on our findings, miR-
122 may be a contributor to stroke resistance in the
SHRSR strain.
Importantly, to further support our hypothesis, we
presently provide a clear cut in vitro demonstration of the
significant protective effect of exogenous administration of
miR-122 on cell survival upon exposure to stress stimuli. In
particular, we showed that the overexpression of miR-122
was able to rescue the cell death induced by both excess NaCl
and hydrogen peroxide in a line of brain endothelial cells. Of
note, the exposure to excess NaCl mimicked the in vivo
administration of HS diet to SHRSP.
The overall findings of our investigation suggest that
miR-122 plays a contributory role in the pathogenesis of
cerebrovascular disease, therefore supporting previous evi-
dence [6, 9]. In fact, miR-122 was shown to be downregulated
both in animal models of ischemic stroke, including the
MCAO rat model [7, 8], and in peripheral blood cells of
patients suffering from ischemic stroke [7, 10, 11]. In addi-
tion, the exogenous administration of miR-122 to MCAO
rats reduced the brain infarct size and the neurological
deficits with improvement of stroke outcomes [9]. Consis-
tently with our current evidence, the miRNA-122 has been
involved in the regulation of inflammation and of cell prolif-
eration through the interference with the NF-kB and toll-like
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Figure 6: Brain histological analysis of SHRSP and SHRSR at the end of 4 weeks of either JD or RD treatment. Representative images of
cortical (cortex) and striatal (striatum) blood vessels in the two strains at the end of 4 weeks of either RD or JD treatment. JD = high-salt
Japanese style diet; RD= regular diet.
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Figure 7: Impact of mimic miRNA-122 overexpression on cell viability, apoptosis, and necrosis in MECs upon exposure to stress stimuli.
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receptor signaling pathways [10]. As a limitation of our
current study, we did not test the impact of exogenous
miR-122 administration on the stroke phenotype occur-
rence of JD-fed SHRSP.
In summary, the different modulation of miR-122 level,
associated with the early signs of cerebrovascular damage,
was detected in the brains of SHRSP after four weeks of the
stroke permissive diet, before the occurrence of cerebrovas-
cular events. Therefore, a decrease of brain miR-122, along
with increased markers of oxidative stress, inflammation,
endothelial dysfunction, apoptosis, and necrosis, can be
considered an early marker of stroke associated with hyper-
tension in our animal model. On the other hand, higher
levels of miR-122, as those found in the brains of SHRSR,
appear to be protective and, in fact, they were able to preserve
cell survival from stress stimuli in vitro.
Our findings support the use of microRNAs, such as
miR-122, as useful biomarkers for stroke prevention and
diagnosis. Moreover, we support the concept that, by iden-
tifying genes and pathways regulated by microRNAs, we
can better understand the mechanisms involved in the
promotion of cerebrovascular damage for a better treat-
ment of stroke.
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